Physician profile
Robert Briski
NPI 1710471966
$2,381.85
in general payments reported to CMS, 2019-2025
12 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $442 · 2023: $173 · 2024: $357 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,099 · Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,099.43 |
| Food and Beverage | $840.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $933.19 | 2022-2025 | |
| Daiichi Sankyo INC. | $285.04 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $212.46 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $197.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $172.26 | 2023-2025 | Enhertu, Calquence |
| Janssen Biotech, INC. | $142.05 | 2025 | Darzalex, Tecvayli |
| Lilly USA, LLC | $122.51 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $115.43 | 2023 | Reblozyl |
| Seagen INC. | $99.99 | 2024 | |
| Genzyme Corporation | $62.47 | 2025 | |
| Merck Sharp & Dohme LLC | $25.21 | 2023 | |
| Gilead Sciences, INC. | $14.12 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Briski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.